Research Reports

Summary

Crescent Biopharma reported $1.0 million in Q1 2026 revenue from a Kelun-Biotech license payment, $23.3 million net loss, and $189.2 million cash as of March 31, 2026, positioning it to fund operations into 2028 while advancing CR-001, CR-002, and CR-003 clinical programs toward key 2027 data readouts.

Key takeaways

Q1 2026 revenue was $1.0 million (vs. $0 in Q1 2025), solely from the $20.0 million upfront payment under the Kelun-Biotech CR-001 license agreement — signaling initial monetization of pipeline assets.

R&D expenses rose 68.7% year-over-year to $17.9 million, reflecting continued investment in CR-001 and CR-002 development — consistent with clinical-stage advancement but increasing near-term cash burn.

Cash and cash equivalents stood at $189.2 million as of March 31, 2026, projected to fund operations into 2028 — providing runway to reach multiple 2027 clinical data milestones without immediate capital raise.

CR-001 ASCEND Phase 1/2 trial is ongoing globally; proof-of-concept data expected Q1 2027, including first-line NSCLC backfill cohort — a near-term catalyst for valuation reassessment.

CR-002 (PD-L1-targeted ADC) is on track for FDA IND submission in mid-2026 and clinic entry in H2 2026, with proof-of-concept data anticipated H2 2027 — expanding the company’s ADC portfolio beyond CR-003.

CR-003 Phase 1/2 trial in China is ongoing with Kelun-Biotech; proof-of-concept data expected Q1 2027, and a CR-003 + CR-001 combination trial is planned for H1 2027 — de-risking development via partner execution.

Full analysis

Crescent Biopharma’s Q1 2026 financial results reflect its transition from preclinical R&D to early-stage commercial partnership execution, anchored by the $20.0 million upfront payment from Kelun-Biotech for CR-001 rights in Greater China — recognized as $1.0 million in revenue for the quarter due to accounting treatment under ASC 606. The 68.7% YoY increase in R&D expenses ($17.9M vs. $10.6M) directly supports ongoing global ASCEND enrollment for CR-001 and preparation for CR-002’s IND filing, while G&A more than doubled ($7.9M vs. $3.6M) due to public-company costs and share-based compensation. Net loss widened to $23.3M (from $15.1M), though per-share loss improved dramatically to $(0.70) from $(19.63) due to a 41.7x increase in weighted-average ordinary shares outstanding (30.4M vs. 0.8M), reflecting prior financings and warrant conversions. Critically, the $189.2M cash balance — down from $213.2M at year-end — remains sufficient to fund operations into 2028, enabling execution against a tightly sequenced clinical roadmap: CR-001 monotherapy and chemo-combination data in Q1/Q2 2027, CR-002’s clinic entry in H2 2026, and CR-003’s China-based proof-of-concept in Q1 2027. Management emphasized the strategic leverage of the Kelun-Biotech collaboration — not only for CR-001 development in China but also for upcoming ADC combinations — underscoring a capital-efficient model where partner funding offsets internal burn while de-risking geographic and modality expansion. No forward revenue or EPS guidance was provided; all forward-looking statements relate to clinical timing and data readouts, not financial projections.